1. Pollmann R, Schmidt T, Eming R, Hertl M. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. Clin Rev Allergy Immunol. 2018;54(1):1-25.
2. Li H, Lin L, Zhang JC. Effects of serum from different subtypes of pemphigus on the expression of desmoglein-3 in HaCaT cells. Chinese journal of Leprosy and Skin Diseases. 2015;31(03):131-135.
3. Hodgson TA, Malik F, Hegarty AM, Porter SR. Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris. Eur J Dermatol. 2003;13(2):142-144.
4. Gach JE, Ilchyshyn A. Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris. Clin Exp Dermatol. 2004;29(3):271-272.
5. Termeer CC, Technau K, Augustin M, Simon JC. Topical tacrolimus (protopic) for the treatment of a localized pemphigus foliaceus. J Eur Acad Dermatol Venereol. 2004;18(5):636-637.
6. Busing V, Kern JS, Bruckner-Tuderman L, Hofmann SC. Recalcitrant pemphigus vulgaris responding to systemic tacrolimus. Dermatology. 2010;221(2):122-126.
7. Dastgheib L, Sadati MS, Baghernejhad M. Assessment of the adjuvant effect of tacrolimus in the management of pemphigus vulgaris: A randomized controlled trial. J Dermatolog Treat. 2015;26(1):90-93.
8. Takae Y, Nishikawa T, Amagai M. Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies. Exp Dermatol. 2009; 18(3):252-260.
9. Lanza A, Perillo L, Landi C, Femiano F, Gombos F, Cirillo N. Controversial role of antibodies against linear epitopes of desmoglein 3 in pemphigus vulgaris, as revealed by semiquantitative living cell immunofluorescence microscopy and in-cell ELISA. Int J Immunopathol Pharmacol. 2010;23(4):1047-1055.
10. Mao X, Li H, Sano Y, Gaestel M, Mo Park J, Payne AS. MAPKAP kinase 2 (MK2)-dependent and -independent models of blister formation in pemphigus vulgaris. J Investig Dermatol Symp Proc. 2014;134(1):68-76.
11. Dehner C, Rotzer V, Waschke J, Spindler V. A desmoplakin point mutation with enhanced keratin association ameliorates pemphigus vulgaris autoantibody-mediated loss of cell cohesion. Am J Pathol. 2014;184(9):2528-2536.
12. Narbutt J, Boncela J, Smolarczyk K, Kowalewski C, Wozniak K, Torzecka JD, et al. Pathogenic activity of circulating anti-desmoglein-3 autoantibodies isolated from pemphigus vulgaris patients. Arch Med Sci. 2012;8(2):347-356.
13. Szabados H, Bosze S, Sillo P, Karpati S, Hudecz F, Uray K. The mapping of linear B-cell epitope regions in the extracellular parts of the desmoglein 1 and 3 proteins: recognition of immobilized peptides by pemphigus patients' serum autoantibodies. J Pept Sci. 2013;19(2):84-94.
14. Berkowitz P, Chua M, Liu Z, Diaz LA, Rubenstein DS. Autoantibodies in the autoimmune disease pemphigus foliaceus induce blistering via p38 mitogen-activated protein kinase-dependent signaling in the skin. Am J Pathol. 2008;173(6):1628-1636.
15. Madan V, Griffiths CE. Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther. 2007;20(4):239-250.
16. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1(2):147-153.
17. Lan CC, Fang AH, Wu PH, Wu CS. Tacrolimus abrogates TGF-beta1-induced type I collagen production in normal human fibroblasts through suppressing p38MAPK signalling pathway: implications on treatment of chronic atopic dermatitis lesions. J Eur Acad Dermatol Venereol. 2014;28(2):204-215.
18. Aomatsu T, Imaeda H, Takahashi K, Fujimoto T, Kasumi E, Yoden A, et al. Tacrolimus (FK506) suppresses TNF-alpha-induced CCL2 (MCP-1) and CXCL10 (IP-10) expression via the inhibition of p38 MAP kinase activation in human colonic myofibroblasts. Int J Mol Med. 2012; 30(5):1152-1158.
19. Choe JY, Lee SJ, Park SH, Kim SK. Tacrolimus (FK506) inhibits interleukin-1β-induced angiopoietin-1, Tie-2 receptor, and vascular endothelial growth factor through down-regulation of JNK and p38 pathway in human rheumatoid fibroblast-like synoviocytes. Joint Bone Spine. 2012;79(2):137-143.
20. Waschke J, Spindler V. Desmosomes and extradesmosomal adhesive signaling contacts in pemphigus. Med Res Rev. 2014;34(6):1127-1145.
21. Amagai M, Stanley JR. Desmoglein as a Target in Skin Disease and Beyond. J Invest Dermatol. 2012;132(3, Pt 2):776-784.
22. Tsunoda K, Ota T, Aoki M, Yamada T, Nagai T, Nakagawa T, et al. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol. 2003;170(4):2170-2178.
23. Mahoney MG, Wang Z, Rothenberger K, Koch PJ, Amagai M, Stanley JR. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest. 1999;103(4):461-468.
24. Sinha AA, Sajda T. The Evolving Story of Autoantibodies in Pemphigus Vulgaris: Development of the "Super Compensation Hypothesis". Front Med (Lausanne). 2018;5:218
25. Sharma P, Mao XM, Payne AS. Beyond steric hindrance: The role of adhesion signaling pathways in the pathogenesis of pemphigus. J Dermatol Sci. 2007;48(1):1-14.
26. Chernyavsky AI, Arredondo J, Piser T, Karlsson E, Grando SA. Differential coupling of M1 muscarinic and alpha7 nicotinic receptors to inhibition of pemphigus acantholysis. J Biol Chem. 2008;283(6):3401-3408.
27. Kalantari-Dehaghi M, Chen Y, Deng W, Chernyavsky A, Marchenko S, Wang PH, et al. Mechanisms of mitochondrial damage in keratinocytes by pemphigus vulgaris antibodies. J Biol Chem. 2013;288(23):16916-16925.
28. Fuchs M, Foresti M, Radeva MY, Kugelmann D, Keil R, Hatzfeld M, et al. Plakophilin 1 but not plakophilin 3 regulates desmoglein clustering.Cell Mol Life Sci. 2019;76(17):3465-3476.
29. Rafei D, Muller R, Ishii N, Llamazares M, Hashimoto T, Hertl M, et al. IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion. Am J Pathol. 2011;178(2):718-723.
30. Ding L, Wang X, Hong X, Lu L, Liu D. IL-36 cytokines in autoimmunity and inflammatory disease. Oncotarget. 2018;9(2):2895-2901.
31. Das D, Anand V, Khandpur S, Sharma VK, Sharma A. T helper type 1 polarizing gammadelta T cells and Scavenger receptors contribute to the pathogenesis of Pemphigus vulgaris. Immunology. 2018;153(1):97-104.
32. Kalantari-Dehaghi M, Anhalt GJ, Camilleri MJ, Chernyavsky AI, Chun S, Felgner PL, et al. Pemphigus vulgaris autoantibody profiling by proteomic technique. PloS one. 2013;8(3):e57587.
33. Fujimura T, Kakizaki A, Furudate S, Aiba S. A possible interaction between periostin and CD163(+) skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid. Exp Dermatol. 2017;26(12):1193-1198.
34. Chernyavsky AI, Arredondo J, Kitajima Y, Sato-Nagai M, Grando SA. Desmoglein versus non-desmoglein signaling in pemphigus acantholysis: characterization of novel signaling pathways downstream of pemphigus vulgaris antigens. J Biol Chem. 2007;282(18):13804-13812.
35. Cirillo N, Campisi G, Gombos F, Perillo L, Femiano F, Lanza A. Cleavage of desmoglein 3 can explain its depletion from keratinocytes in pemphigus vulgaris. Exp Dermatol.2008;17(10):858-863.